Design of the Tocilizumab in Giant Cell Arteritis Trial

Overview. The GiACTA trial is a multicenter, randomized, double-blind, and placebo-controlled study designed to test the ability of tocilizumab (TCZ), an interleukin (IL)-6 receptor antagonist, to maintain disease remission in patients with giant cell arteritis (GCA). Design. Approximately 100 cente...

Descripción completa

Detalles Bibliográficos
Autores principales: Unizony, Sebastian H., Dasgupta, Bhaskar, Fisheleva, Elena, Rowell, Lucy, Schett, Georg, Spiera, Robert, Zwerina, Jochen, Harari, Olivier, Stone, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638687/
https://www.ncbi.nlm.nih.gov/pubmed/23653652
http://dx.doi.org/10.1155/2013/912562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638687/
https://www.ncbi.nlm.nih.gov/pubmed/23653652
http://dx.doi.org/10.1155/2013/912562

Ejemplares similares